Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus
NCT ID: NCT06727721
Last Updated: 2024-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
10 participants
INTERVENTIONAL
2023-11-06
2029-12-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The placebo group
The control group was given albumin
albumin injection
Placebo
The control group
The control group was given mesenchymal stem cells
Mesenchymal stem cells
Ordinary mesenchymal stem cells were given
The experimental group
The experimental group was given OCN-19 stem cells
mesenchymal stem cells with OCN-19
The patient received mesenchymal stem cells with OCN-19 three times
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mesenchymal stem cells with OCN-19
The patient received mesenchymal stem cells with OCN-19 three times
Mesenchymal stem cells
Ordinary mesenchymal stem cells were given
albumin injection
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able to clearly understand the purpose of clinical trials and comply with trial requirements, willing to participate in this study, and sign an informed consent form;
3. 20kg/m2 ≤ Body Mass Index (BMI) ≤ 30 kg/m2;
4. 7.5% ≤ glycated hemoglobin ≤ 10%;
5. Insulin should be subcutaneously injected for more than six months, and insulin and/or other oral hypoglycemic drugs (limited to metformin only) should be used α The dosage of glycosidase inhibitors remained stable for the first 3 months before randomization;
6. During the study period, all males and females with reproductive potential were willing to accept the use of efficient contraceptive methods.
Exclusion Criteria
2. Patients with severe allergic constitution or allergic to any ingredients used in cell culture;
3. Patients who have used drugs that affect glucose metabolism within the past month, such as glucocorticoids, thiazide diuretics, oral contraceptives, tricyclic antidepressants, etc;
4. Screening the patients with acute complications such as diabetes ketoacidosis and non ketotic hyperosmolar syndrome in recent 6 months;
5. Serious cardiovascular and cerebrovascular events such as NYHA grade III or IV heart failure, myocardial infarction, cerebral infarction, and cerebral hemorrhage occurred within the past 6 months;
6. Patients with abnormal blood routine (including white blood cell or neutrophil count below the lower limit of normal, abnormal platelet count, and hemorrhagic disease);
7. Patients with liver and kidney dysfunction: such as serum bilirubin TBIL exceeding the upper limit of normal by 1.5 times, AST and ALT exceeding the upper limit of normal by 2.5 times, and serum creatinine exceeding 1.5 mg/dl for males and 1.4 mg/dl for females;
8. Patients with other serious systemic diseases (such as malignant tumors, central nervous system, cardiovascular system, blood system, digestive system, endocrine system, respiratory system, urogenital system, immune system, etc.);
9. Individuals who are currently using systemic hormones (such as glucocorticoids), immunosuppressants, or cytotoxic therapy;
10. Patients who received antibiotic treatment within the three months prior to study registration;
11. Patients who have received live or attenuated vaccines within 4 weeks prior to registration, or plan to receive live or attenuated vaccines during the study period;
12. Patients who are positive for HbsAg, Anti HCV, HIV or syphilis;
13. Patients with active infection (such as hepatitis B or hepatitis C, tuberculosis) requiring treatment;
14. Fever related diseases of unknown origin;
15. Disabled patients (blind, deaf, mute, intellectually disabled, physically disabled) and individuals with mental illnesses;
16. Patients who use drugs or have a history of adverse drug abuse and alcohol dependence within 5 years (with mental or substance abuse disorders that may interfere with the requirements of the trial);
17. Patients of childbearing age who are pregnant or lack effective contraceptive measures or have a pregnancy plan, as well as breastfeeding patients;
18. Patients who have received other stem cell treatments or participated in other clinical studies within the first three months of screening;
19. Patients who have not recovered due to adverse events (≥ level 2) caused by drug treatment within 4 weeks prior to the start of the study;
20. Patients with congenital or acquired immune dysfunction or a history of organ transplantation;
21. Patients with other serious diseases that may affect infusion results;
22. According to the judgment of the researchers, patients whose clinical conditions are not suitable for inclusion in this study.-
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lu jin ，MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lu jin ，MD
Director of endocrinology Department, Changhai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changhai Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
jin lu
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHEC2023-226
Identifier Type: -
Identifier Source: org_study_id